

AMENDMENTS TO THE CLAIMS

Claims 1 to 40. (Cancelled)

41. (Previously Presented) A kit for use in linearly amplifying mRNA, said kit comprising:
- (a) an oligonucleotide promoter-primer comprising an RNA polymerase promoter sequence;
 - (b) an RNaseH- polymerase;
 - (c) an RNaseH+ polymerase; and
 - (d) a reverse transcriptase inhibitor.

42. (Previously Presented) The kit according to Claim 41, wherein said kit further comprises:
- instructions to convert the mRNA to cDNA, and to then transcribe the cDNA into RNA in the presence of a reverse transcriptase that is rendered incapable of RNA-dependent DNA polymerase activity during this transcription step.

Claims 43-45 (Cancelled).

46. (Previously Presented) The kit according to Claim 41, wherein said kit further comprises MMLV-RT.
47. (Previously Presented) The kit according to Claim 46, wherein said kit further comprises an RNA polymerase.
48. (Previously Presented) The kit according to Claim 47, wherein said RNA polymerase is T7 RNA polymerase.
49. (Previously Presented) The kit according to Claim 41, wherein said reverse transcriptase inhibitor is at least one ddNTP.
50. (Previously Presented) The kit according to Claim 49, wherein said reverse

transcriptase inhibitor comprises ddNTPs.

51. (Previously Presented) The kit according to Claim 50, wherein said ddNTPs are selected from ddATP, ddTTP, ddCTP and ddGTP.

52. (Previously Presented) The kit according to Claim 51, wherein said ddNTPs are selected from ddATP and ddGTP.

53. (Previously Presented) A kit for use in linearly amplifying mRNA, said kit comprising:

- (a) an oligonucleotide promoter-primer comprising an RNA polymerase promoter sequence;
- (b) an RNaseH- polymerase;
- (c) an RNaseH+ polymerase;
- (d) ddNTPs; and
- (e) an RNA polymerase.

Claims 54-55 (Canceled)

56. (Previously Presented) The kit according to Claim 53, wherein said RNA polymerase is T7 RNA polymerase.

57. (Previously Presented) The kit according to Claim 53, wherein said kit further comprises:

instructions to convert the mRNA to cDNA, and to then transcribe the cDNA into RNA in the presence of a reverse transcriptase that is rendered incapable of RNA-dependent DNA polymerase activity during this transcription step.

58. (Previously Presented) The kit according to Claim 53, wherein said kit further comprises MMLV-RT.

59. (Previously Presented) A kit for use in linearly amplifying mRNA, said kit comprising:

Atty Dkt. No.: 10990638-2
USSN: 09/690,173

- (a) an oligonucleotide promoter-primer comprising an RNA polymerase promoter sequence; and
- (b) a reverse transcriptase inhibitor.

60. (Previously Presented) The kit according to Claim 59, wherein said reverse transcriptase inhibitor is at least one ddNTP.

61. (Previously Presented) The kit according to Claim 59, wherein said reverse transcriptase inhibitor comprises ddNTPs.

62. (Previously Presented) The kit according to Claim 61, wherein said ddNTPs are selected from ddATP, ddTTP, ddCTP and ddGTP.

63. (Previously Presented) The kit according to Claim 59, wherein said kit further comprises:

instructions to convert the mRNA to cDNA, and to then transcribe the cDNA into RNA in the presence of a reverse transcriptase that is rendered incapable of RNA-dependent DNA polymerase activity during this transcription step.